Physician profile
Albert D Mims
NPI 1609972314
$450.01
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $28.17 · 2022: $14.95 · 2024: $24.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.53 | 2019 | |
| Astellas Pharma US INC | $36.75 | 2019 | |
| Hikma Pharmaceuticals USA | $36.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.99 | 2019 | |
| Amarin Pharma, INC. | $28.17 | 2020 | |
| Sunovion Pharmaceuticals INC. | $25.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.26 | 2019 | |
| Vital Connect, INC | $24.80 | 2024 | Vitalpatch Rtm |
| Irhythm Technologies, INC. | $16.51 | 2019 | |
| Abbvie INC. | $14.95 | 2022 | |
| Genentech USA, INC. | $14.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2019 | |
| Pfizer INC. | $12.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.93 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.85 | 2019 | |
| Merck Sharp & Dohme LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.